登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
ClinicalTrials.gov 上登记的一项肺癌开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07819591,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed relapsed small-cell lung cancer after failure of platinum-based chemotherapy and PD-1/PD-L1 monoclonal antibody treatment.
入选标准第 3 条
Recovery of prior anti-tumor therapy toxicities to ≤ Grade 1 (NCI-CTCAE v5.0), except alopecia, fatigue, hyperpigmentation, and stabilized thyroid dysfunction (on hormone replacement) as specified in protocol.
入选标准第 7 条
Effective contraception from screening through 6 months after end of treatment for all patients with reproductive potential.
入选标准第 14 条
ECOG performance status 0 or 1.
入选标准第 5 条
Total bilirubin ≤ 1.5×ULN (≤ 3×ULN if liver metastases); AST and ALT ≤ 2.5×ULN (≤ 5.0×ULN if liver metastases).
入选标准第 10 条
Creatinine ≤ 1.5×ULN or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault).
入选标准第 11 条
INR ≤ 1.5; APTT ≤ 1.5×ULN.
入选标准第 12 条
At least one measurable lesion according to RECIST v1.1.
入选标准第 4 条
Other malignancy within 5 years, except adequately controlled basal cell carcinoma, cervical CIS, or DCIS >3 years.
排除标准第 13 条
Women of childbearing potential: negative pregnancy test within 7 days before first dosing and non-lactating.
入选标准第 13 条
Pregnancy or breastfeeding.
排除标准第 23 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07819591,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Patients who have signed informed consent and agree to comply with the protocol. Age ≥ 18 years. Histologically or cytologically confirmed relapsed small-cell lung cancer after failure of platinum-based chemotherapy and PD-1/PD-L1 monoclonal antibody treatment. At least one measurable lesion according to RECIST v1.1. ECOG performance status 0 or 1. Expected survival time ≥ 3 months. Recovery of prior anti-tumor therapy toxicities to ≤ Grade 1 (NCI-CTCAE v5.0), except alopecia, fatigue, hyperpigmentation, and stabilized thyroid dysfunction (on hormone replacement) as specified in protocol. Adequate cardiac function: left ventricular ejection fraction (LVEF) ≥ 50%. Adequate organ function: ANC ≥ 1.5×10\^9/L, platelets ≥ 100×10\^9/L, hemoglobin ≥ 90 g/L. Total bilirubin ≤ 1.5×ULN (≤ 3×ULN if liver metastases); AST and ALT ≤ 2.5×ULN (≤ 5.0×ULN if liver metastases). Creatinine ≤ 1.5×ULN or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault). INR ≤ 1.5; APTT ≤ 1.5×ULN. Women of childbearing potential: negative pregnancy test within 7 days before first dosing and non-lactating. Effective contraception from screening through 6 months after end of treatment for all patients with reproductive potential.排除标准:Exclusion Criteria:
History of hypersensitivity to paclitaxel micelles, ivonescimab (YS11/YS), or components of these investigational products, or structurally related agents. Prior systemic therapy with taxanes and/or anti-VEGF monoclonal antibodies. Major surgery within 28 days before first investigational treatment. Antitumor treatment within 4 weeks (or 5 half-lives for biologics, whichever is shorter), including chemotherapy, targeted therapy, biologics, immunotherapy, curative radiotherapy, major surgery, or large-field radiotherapy; small-molecule targeted therapy within 5 days before first dose (as protocol details). Use of CYP3A/CYP2C inhibitors or inducers within 7 days before first dose, or need to continue during study. Use of traditional Chinese anti-tumor herbal medicines within 7 days before first dose, or need to continue during study. Ongoing use of drugs known to prolong QT interval or induce torsades during study. Symptomatic CNS involvement (including symptomatic brain metastases); brain-metastasis patients previously on steroids must be tapered and off steroids for ≥14 days unless protocol allows exceptions. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage. Tumor encasement/invasion of major thoracoabdominal/other vital vessels judged unsafe for protocol treatment. Clinically significant bleeding within 3 weeks before informed consent (e.g., hemoptysis, GI bleeding, bleeding ulcer). Inflammatory bowel disease, major bowel resection history, immune-related colitis, bowel obstruction, chronic diarrhea, or Gilbert syndrome. Other malignancy within 5 years, except adequately controlled basal cell carcinoma, cervical CIS, or DCIS >3 years. Serious cardiac/cerebrovascular disease: NYHA class ≥2 heart failure, acute coronary syndrome within 6 months, or stroke/TIA/hemorrhagic stroke within 6 months. Significant arrhythmia (complete LBBB, third-degree AV block, uncontrolled ventricular/atrial arrhythmia; stable controlled arrhythmia exceptions may apply). Active unstable thromboembolic disease requiring treatment within 6 months (except >4-week old peripheral line thrombosis). Uncontrolled systemic diseases likely to interfere with protocol conduct, including uncontrolled hypertension, diabetes, active bleeding, active hepatitis B/C/HIV (including HBV DNA >10000 copies/mL when HBsAg positive), or other active infection. Autoimmune disease requiring systemic treatment in prior 2 years (excluding replacement hormones). Current or clinically significant history of ILD, or ILD/grade ≥2 radiation pneumonitis. Severe neurologic or psychiatric disease. Unhealed wound, ulcer, or fracture within 4 weeks before informed consent. Planned or received live vaccine within 28 days before randomization/first dose. Pregnancy or breastfeeding. Any other condition the investigator judges to make trial participation inappropriate.
引自 ClinicalTrials.gov, NCT07819591, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07819591,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。